blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2265612

EP2265612 - SUBSTITUTED XANTHINE DERIVATIVES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  09.02.2018
Database last updated on 07.10.2024
FormerThe patent has been granted
Status updated on  03.03.2017
FormerGrant of patent is intended
Status updated on  16.01.2017
Most recent event   Tooltip26.06.2020Lapse of the patent in a contracting state
New state(s): CY, MK		published on 29.07.2020  [2020/31]
Applicant(s)For all designated states
CONCERT PHARMACEUTICALS, INC.
99 Hayden Avenue, Suite 500
Lexington, MA 02421 / US
[2016/44]
Former [2010/52]For all designated states
Concert Pharmaceuticals Inc.
99 Hayden Avenue, Suite 500
Lexington, MA 02421 / US
Inventor(s)01 / TUNG, Roger, D.
3 Burnham Road
Lexington MA 02420 / US
02 / LIU, Julie, F.
3 Whitman Circle
Lexington MA 02420 / US
03 / HARBESON, Scott, L.
203 Pemberton Street, Apt. 5
Cambridge MA 02140 / US
 [2017/14]
Former [2010/52]01 / TUNG, Roger, D.
3 Burnham Road
Lexington MA 02420 / US
02 / LIU, Julie, F.
3 Whitman Circle
Lexington MA 02420 / US
03 / HARBESON, Scott, L.
203 Pemberton Street Apt. 5
Cambridge MA 02140 / US
Representative(s)D Young & Co LLP
3 Noble Street
London EC2V 7BQ / GB
[N/P]
Former [2017/14]D Young & Co LLP
120 Holborn
London EC1N 2DY / GB
Former [2010/52]Mallalieu, Catherine Louise
D Young & Co LLP 120 Holborn
London EC1N 2DY / GB
Application number, filing date09715566.727.02.2009
[2010/52]
WO2009US01294
Priority number, dateUS20080067736P29.02.2008         Original published format: US 67736 P
US20080134568P11.07.2008         Original published format: US 134568 P
US20080198715P07.11.2008         Original published format: US 198715 P
[2010/52]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2009108375
Date:03.09.2009
Language:EN
[2009/36]
Type: A1 Application with search report 
No.:EP2265612
Date:29.12.2010
Language:EN
The application published by WIPO in one of the EPO official languages on 03.09.2009 takes the place of the publication of the European patent application.
[2010/52]
Type: B1 Patent specification 
No.:EP2265612
Date:05.04.2017
Language:EN
[2017/14]
Search report(s)International search report - published on:EP03.09.2009
ClassificationIPC:C07D473/06, A61K31/522, A61P1/16, A61P13/12
[2010/52]
CPC:
C07D473/10 (EP,US); A61P1/02 (EP); A61P1/04 (EP);
A61P1/16 (EP); A61P13/02 (EP); A61P13/12 (EP);
A61P19/06 (EP); A61P21/04 (EP); A61P25/00 (EP);
A61P25/24 (EP); A61P27/02 (EP); A61P3/00 (EP);
A61P3/04 (EP); A61P3/06 (EP); A61P3/10 (EP);
A61P31/12 (EP); A61P31/18 (EP); A61P33/02 (EP);
A61P35/00 (EP); A61P37/02 (EP); A61P7/02 (EP);
A61P9/00 (EP); A61P9/10 (EP); A61P9/12 (EP);
C07D473/04 (EP,US); C07B2200/05 (US); C07B2200/07 (US);
Y02A50/30 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2017/14]
Former [2010/52]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:SUBSTITUIERTE XANTHINDERIVATE[2010/52]
English:SUBSTITUTED XANTHINE DERIVATIVES[2010/52]
French:DÉRIVÉS DE XANTHINE SUBSTITUÉS[2010/52]
Entry into regional phase27.09.2010National basic fee paid 
27.09.2010Designation fee(s) paid 
27.09.2010Examination fee paid 
Examination procedure27.09.2010Examination requested  [2010/52]
17.06.2011Amendment by applicant (claims and/or description)
30.07.2013Despatch of a communication from the examining division (Time limit: M06)
04.02.2014Reply to a communication from the examining division
29.08.2014Despatch of a communication from the examining division (Time limit: M06)
05.03.2015Reply to a communication from the examining division
27.10.2015Despatch of a communication from the examining division (Time limit: M06)
16.03.2016Reply to a communication from the examining division
06.10.2016Communication of intention to grant the patent
13.01.2017Receipt of the translation of the claim(s)
06.02.2017Fee for grant paid
06.02.2017Fee for publishing/printing paid
Divisional application(s)EP17160882.1  / EP3199203
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  30.07.2013
Opposition(s)08.01.2018No opposition filed within time limit [2018/11]
Fees paidRenewal fee
23.02.2011Renewal fee patent year 03
24.02.2012Renewal fee patent year 04
27.02.2013Renewal fee patent year 05
27.02.2014Renewal fee patent year 06
26.02.2015Renewal fee patent year 07
26.02.2016Renewal fee patent year 08
27.02.2017Renewal fee patent year 09
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU27.02.2009
AT05.04.2017
CY05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
MK05.04.2017
NL05.04.2017
PL05.04.2017
PT05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
[2020/31]
Former [2020/27]HU27.02.2009
AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
PT05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2020/15]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
TR05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/44]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
MC05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/25]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SI05.04.2017
SK05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/11]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
IT05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SK05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/10]AT05.04.2017
CZ05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
RO05.04.2017
SE05.04.2017
SK05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2018/09]AT05.04.2017
DK05.04.2017
EE05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
SE05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/50]AT05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
LV05.04.2017
NL05.04.2017
PL05.04.2017
SE05.04.2017
BG05.07.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/49]AT05.04.2017
ES05.04.2017
FI05.04.2017
HR05.04.2017
LT05.04.2017
NL05.04.2017
NO05.07.2017
GR06.07.2017
IS05.08.2017
Former [2017/48]NL05.04.2017
Cited inInternational search[X]WO8700523  (HOECHST AG [DE]) [X] 1,9-11,13,14,17 * page 3, line 1 - line 10; claims 1,9 *;
 [X]US5112827  (SAUNDERS J PALMER [US], et al) [X] 1,9-11,13,17,18 * claims 3-7,13 *;
 [X]US5648357  (BIANCO JAMES A [US], et al) [X] 1,9-11,13,15,16 * claim 10 *;
 [X]US6316458  (NADLER JERRY L [US], et al) [X] 1,9-11,13,22 * examples 3-5; claims 1-12 *;
 [X]  - WARD ET AL, "Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties and its therapeutic effects", DRUGS, ADIS INTERNATIONAL LTD, (19870101), vol. 34, ISSN 0012-6667, pages 50 - 97, XP009118505 [X] 1,9-11,13-15,18-22 * page 58-60, paragraph 1.2.2-1.2.4 page 61, paragraph 1.3.1 page 65, paragraph 1.7 page 74, paragraph 3.1.6 *

DOI:   http://dx.doi.org/10.2165/00003495-198734010-00003
 [Y]  - KUSHNER DJ ET AL, "Pharmacological uses and perspectives of heavy water and deuterated compounds", CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, OTTAWA, ONT, CA, (19990201), vol. 77, no. 2, pages 79 - 88, XP009086918 [Y] 1,9-11 * the whole document *
 [Y]  - FOSTER A B, "Deuterium isotope effects in the metabolism of drugs and xenobiotics: implications for drug design", ADVANCES IN DRUG RESEARCH, ACADEMIC PRESS, LONDON, GB, (19850101), vol. 14, ISSN 0065-2490, pages 1 - 40, XP009086953 [Y] 1,9-11 * the whole document *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.